Transcriptional regulation of human USP24 gene expression by NF-kappa B

Journal of Neurochemistry

Volumn 128, Issue 6, 2014, Pages 818-828

  Wang, Ke ^a   Liu, Shengchun ^b   Wang, Juelu ^a   Wu, Yili ^b   Cai, Fang ^a   Song, Weihong ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

NF B; transcription; ubiquitin; USP24

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 1; STAT3 PROTEIN; T CELL TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA FLANKING REGION; EMBRYO; GENE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; USP24 GENE;

NFΚB; TRANSCRIPTION; UBIQUITIN; USP24;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CHROMOSOME MAPPING; CLONING, MOLECULAR; DNA-BINDING PROTEINS; HEK293 CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEUROBLASTOMA; NF-KAPPA B; PARKINSON DISEASE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION INITIATION SITE; TRANSCRIPTIONAL ACTIVATION; UBIQUITIN THIOLESTERASE;

EID: 84895928658     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12626     Document Type: Article

References (66)

1. Amerik A., Swaminathan S., Krantz B. A., Wilkinson K. D., and, Hochstrasser M., (1997) In vivo disassembly of free polyubiquitin chains by yeast Ubp14 modulates rates of protein degradation by the proteasome. EMBO J. 16, 4826-4838.
2. Baek S. H., Choi K. S., Yoo Y. J., Cho J. M., Baker R. T., Tanaka K., and, Chung C. H., (1997) Molecular cloning of a novel ubiquitin-specific protease, UBP41, with isopeptidase activity in chick skeletal muscle. J. Biol. Chem. 272, 25560-25565.
3. Baeuerle P. A., and, Baltimore D., (1988) I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242, 540-546.
4. Baiguera C., Alghisi M., Pinna A,. et al. (2012) Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. Brain 135, 2750-2765.
5. Baldi L., Brown K., Franzoso G., and, Siebenlist U., (1996) Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. J. Biol. Chem. 271, 376-379.
6. Bennett M. C., Bishop J. F., Leng Y., Chock P. B., Chase T. N., and, Mouradian M. M., (1999) Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274, 33855-33858.
7. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., and, Hirsch E. C., (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172, 151-154.
8. Brito D. A., and, Rieder C. L., (2006) Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr. Biol. 16, 1194-1200.
9. Cai F., Chen B., Zhou W., Zis O., Liu S., Holt R. A., Honer W. G., and, Song W,. (2008) SP1 regulates a human SNAP-25 gene expression. J. Neurochem. 105, 512-523.
10. Chesnel F., Bazile F., Pascal A., and, Kubiak J. Z., (2006) Cyclin B dissociation from CDK1 precedes its degradation upon MPF inactivation in mitotic extracts of Xenopus laevis embryos. Cell Cycle 5, 1687-1698.
11. Christensen M. A., Zhou W., Qing H., Lehman A., Philipsen S., and, Song W., (2004) Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol. Cell. Biol. 24, 865-874.
12. Conway K. A., Harper J. D., and, Lansbury P. T., (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
13. D'Andrea A., and, Pellman D., (1998) Deubiquitinating enzymes: a new class of biological regulators. Crit. Rev. Biochem. Mol. Biol. 33, 337-352.
14. Dehmer T., Heneka M., Sastre M., Dichgans J., and, Schulz J., (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88, 494-501.
15. DeStefano A. L., Lew M. F., Golbe L. I., et al,. (2002) PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am. J. Hum. Genet. 70, 1089-1095.
16. Fischer-Vize J. A., Rubin G. M., and, Lehmann R., (1992) The fat facets gene is required for Drosophila eye and embryo development. Development 116, 985-1000.
17. Gai W. P., Blessing W. W., and, Blumbergs P. C., (1995) Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. Brain 118, 1447-1459.
18. Gao H., Liu B., Zhang W., and, Hong J., (2003) Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24, 395-401.
19. Gao F., Chen D., Hu Q., and, Wang G,. (2013) Rotenone directly induces BV2 cell activation via the p38 MAPK pathway. PLoS ONE 8, e72046.
20. Ghosh S., May M., and, Kopp E., (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260.
21. Ghosh A., Roy A., Liu X., et al,. (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 104, 18754-18759.
22. Haas A. L., Warms J. V., Hershko A., and, Rose I. A., (1982) Ubiquitin-activating enzyme. Mechanism and role in protein-ubiquitin conjugation. J. Biol. Chem. 257, 2543-2548.
23. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V. M., Trojanowski J. Q., Mann D., and, Iwatsubo T., (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277, 49071-49076.
24. Hicks A. A., Petursson H., Jonsson T., et al,. (2002) A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52, 549-555.
25. Hunot S., Brugg B., Ricard D., Michel P., Muriel M., Ruberg M., Faucheux B., Agid Y., and, Hirsch E., (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl Acad. Sci. USA 94, 7531-7536.
26. Imai Y., Soda M., and, Takahashi R., (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275, 35661-35664.
27. Jankovic J., (2005) Searching for a relationship between manganese and welding and Parkinson's disease. Neurology 64, 2021-2028.
28. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and, Shimizu N., (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
29. Korner M., Tarantino N., Pleskoff O., Lee L. M., and, Debre P., (1994) Activation of nuclear factor kappa B in human neuroblastoma cell lines. J. Neurochem. 62, 1716-1726.
30. Lai B. C., Marion S. A., Teschke K., and, Tsui J. K., (2002) Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat. Disord. 8, 297-309.
31. Lam Y. A., Xu W., DeMartino G. N., and, Cohen R. E., (1997) Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature 385, 737-740.
32. de Lau L. M., and, Breteler M. M., (2006) Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535.
33. Leroy E., Boyer R., Auburger G., et al,. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
34. Li Y. J., Scott W. K., Hedges D. J., et al,. (2002) Age at onset in two common neurodegenerative diseases is genetically controlled. Am. J. Hum. Genet. 70, 985-993.
35. Li Y. J., Hauser M. A., Scott W. K., et al,. (2004) Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 62, 2005-2009.
36. Li Y., Schrodi S., Rowland C., Tacey K., Catanese J., and, Grupe A., (2006) Genetic evidence for ubiquitin-specific proteases USP24 and USP40 as candidate genes for late-onset Parkinson disease. Hum. Mutat. 27, 1017-1023.
37. Liang Z.-Q., Li Y.-L., Zhao X.-L., Han R., Wang X.-X., Wang Y., Chase T., Bennett M., and, Qin Z.-H., (2007) NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res. 1145, 190-203.
38. Lowe J., Blanchard A., Morrell K., Lennox G., Reynolds L., Billett M., Landon M., and, Mayer R. J., (1988) Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J. Pathol. 155, 9-15.
39. Lowe J., McDermott H., Landon M., Mayer R. J., and, Wilkinson K. D., (1990) Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161, 153-160.
40. Ly P. T., Wu Y., Zou H., et al,. (2013) Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 123, 224-235.
41. Malú G. T., and, Matthew S. G,. (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37, 510-518.
42. Mattson M., and, Meffert M., (2006) Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 13, 852-860.
43. Mogi M., Kondo T., Mizuno Y., and, Nagatsu T., (2007) p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci. Lett. 414, 94-97.
44. Oliveira S. A., Li Y. J., Noureddine M. A., Zuchner S., Qin X., Pericak-Vance M. A., and, Vance J. M., (2005) Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease. Am. J. Hum. Genet. 77, 252-264.
45. Park S., Choi W.-S., Yoon S.-Y., Ahn Y., and, Oh Y., (2004) Activation of NF-kappaB is involved in 6-hydroxydopamine-but not MPP+ -induced dopaminergic neuronal cell death: its potential role as a survival determinant. Biochem. Biophys. Res. Commun. 322, 727-733.
46. Parkinson J,. (2002) An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 14, 223-236; discussion 222.
47. Payami H., and, Zareparsi S., (1998) Genetic epidemiology of Parkinson's disease. J. Geriatr. Psychiatry Neurol. 11, 98-106.
48. Sadoul R., Fernandez P. A., Quiquerez A. L., et al,. (1996) Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J. 15, 3845-3852.
49. Scherer D. C., Brockman J. A., Chen Z., Maniatis T., and, Ballard D. W., (1995) Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc. Natl Acad. Sci. USA 92, 11259-11263.
50. Schwartz L. M., Myer A., Kosz L., Engelstein M., and, Maier C., (1990) Activation of polyubiquitin gene expression during developmentally programmed cell death. Neuron 5, 411-419.
51. Shimura H., Hattori N., Kubo S., et al,. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302-305.
52. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R., and, Goedert M., (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
53. Sun X., Wang Y., Qing H., et al,. (2005) Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J. 19, 739-749.
54. Sun X., He G., Qing H., Zhou W., Dobie F., Cai F., Staufenbiel M., Huang L. E., and, Song W., (2006) Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl Acad. Sci. USA 103, 18727-18732.
55. Surana U., Amon A., Dowzer C., McGrew J., Byers B., and, Nasmyth K., (1993) Destruction of the CDC28/CLB mitotic kinase is not required for the metaphase to anaphase transition in budding yeast. EMBO J. 12, 1969-1978.
56. Verma R., Aravind L., Oania R., McDonald W. H., Yates J. R., 3rd, Koonin E. V., and, Deshaies R. J., (2002) Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298, 611-615.
57. Weinreb P. H., Zhen W., Poon A. W., Conway K. A., and, Lansbury P. T., Jr, (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715.
58. Wilkinson K. D., Lee K. M., Deshpande S., Duerksen-Hughes P., Boss J. M., and, Pohl J., (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246, 670-673.
59. Wilkinson K. D., Deshpande S., and, Larsen C. N., (1992) Comparisons of neuronal (PGP 9.5) and non-neuronal ubiquitin C-terminal hydrolases. Biochem. Soc. Trans. 20, 631-637.
60. Wu Y. R., Chen C. M., Chen Y. C., Chao C. Y., Ro L. S., Fung H. C., Hsiao Y. C., Hu F. J., and, Lee-Chen G. J., (2010) Ubiquitin specific proteases USP24 and USP40 and ubiquitin thiolesterase UCHL1 polymorphisms have synergic effect on the risk of Parkinson's disease among Taiwanese. Clin. Chim. Acta 411, 955-958.
61. Yao T., and, Cohen R. E., (2002) A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 419, 403-407.
62. Yuan Y.-H., Sun J.-D., Wu M.-M., Hu J.-F., Peng S.-Y., and, Chen N.-H., (2013) Rotenone could activate microglia through NFκB associated pathway. Neurochem. Res. 38, 1553-1560.
63. Zhang Y., Gao J., Chung K. K., Huang H., Dawson V. L., and, Dawson T. M., (2000) Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl Acad. Sci. USA 97, 13354-13359.
64. Zhang L., Lubin A., Chen H., Sun Z., and, Gong F., (2012a) The deubiquitinating protein USP24 interacts with DDB2 and regulates DDB2 stability. Cell Cycle 11, 4378-4384.
65. Zhang M., Deng Y., Luo Y., Zhang S., Zou H., Cai F., Wada K., and, Song W., (2012b) Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. J. Neurochem. 120, 1129-1138.
66. Zhou W., and, Song W., (2006) Leaky scanning and reinitiation regulate BACE1 gene expression. Mol. Cell. Biol. 26, 3353-3364.